Hôpital Saint-Louis

Running trials

• Not yet recruiting

  A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

  NCT07612787· Phase 1/2· Centre Hospitalier Universitaire de Saint Etienne· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL

  2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Servier· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

  NCT07359456· Phase 2· UNICANCER· Source

• Recruiting

  A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas

  NCT05685173· Phase 1· Regeneron Pharmaceuticals Inc.· Source

• Recruiting

  Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test

  2025-521045-24-00· Phase 3· Unicancer· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Not yet recruiting

  Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease

  NCT07284394· Phase 3· UNICANCER· Source

• Recruiting

  Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients

  NCT07771855· Phase 2· Hopital Foch· Source

• Not yet recruiting

  A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

  2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

  NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

  NCT07292012· Phase 4· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)

  NCT05986071· Phase 1/2· Institut Paoli-Calmettes· Source

• Not yet recruiting

  Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

  NCT07337447· Phase 2· Hospices Civils de Lyon· Source

• Recruiting

  Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

  NCT07124858· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  Early detection of triple negative breast cancer relapse (CUPCAKE)

  2022-501562-22-01· Phase 2· Institut Curie· Source

• Recruiting

  Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

  NCT06225505· Institut Curie· Source

• Not yet recruiting

  Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma

  NCT07347210· Phase 2· Centre Hospitalier Universitaire de Besancon· Source

• Not yet recruiting

  Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.

  NCT07379957· University Hospital, Bordeaux· Source

• Not yet recruiting

  Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

  NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source

• Recruiting

  Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

  NCT07157670· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

  NCT07044453· Phase 2/3· University Hospital, Rouen· Source

• Recruiting

  Dapagliflozin for Cardio-renal Protection After ICU Discharge

  NCT07025629· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Not yet recruiting

  An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

  NCT06281847· Phase 1/2· Advesya SAS· Source

• Recruiting

  Momelotinib in VEXAS Syndrome

  NCT07098936· Phase 2· Groupe Francophone des Myelodysplasies· Source

• Recruiting

  Momelotinib in VEXAS syndrome

  2024-519779-24-00· Phase 2· Groupe Francophone Des Myelodysplasies· Source

• Recruiting

  A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  NCT07216027· Phase 2· Pfizer· Source

• Recruiting

  Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

  NCT06656598· Phase 2· Intergroupe Francophone de Cancerologie Thoracique· Source

• Not yet recruiting

  FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

  2025-521322-14-00· Phase 2· French Innovative Leukemia Organization· Source

• Recruiting

  Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

  NCT06599411· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

  NCT07407465· Phase 2· Gruppo Oncologico del Nord-Ovest· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Kura Oncology, Inc.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· BeOne Medicines· Source

• Not yet recruiting

  A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

  NCT07082452· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  Study of the Cellular Response Induced After Vaccination Against the Hepatitis B Virus

  NCT06876467· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

  NCT06680596· Phase 2· UNICANCER· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· Phase 3· Celgene· Source

Showing 50 of 271.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer24 recruiting
• Acute myeloid leukaemia21 recruiting
• Childhood cancers14 recruiting
• Myeloproliferative neoplasms14 recruiting
• Multiple myeloma13 recruiting
• Myelodysplastic syndromes10 recruiting
• Acute lymphoblastic leukaemia9 recruiting
• Metastatic breast cancer7 recruiting
• HIV6 recruiting
• Liver and biliary tract cancer6 recruiting
• Melanoma6 recruiting
• Bladder cancer5 recruiting
• Lung cancer5 recruiting
• Pancreatic cancer5 recruiting
• Atopic dermatitis (eczema)4 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Chronic myeloid leukaemia4 recruiting
• Crohn's disease4 recruiting
• Follicular lymphoma4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Kidney cancer4 recruiting
• Prostate cancer4 recruiting
• Aplastic anaemia3 recruiting
• Chronic kidney disease3 recruiting
• Glioblastoma3 recruiting
• Hodgkin lymphoma3 recruiting
• Ovarian cancer3 recruiting
• Dermatomyositis and polymyositis (myositis)2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Hepatitis B2 recruiting
• Hidradenitis suppurativa2 recruiting
• Mantle cell lymphoma2 recruiting
• Triple-negative breast cancer2 recruiting
• Bronchiectasis1 recruiting
• Coeliac disease1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• High blood pressure1 recruiting
• Neuroendocrine tumours1 recruiting
• Psoriasis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  NCT06984328· Phase 2· Genmab A/S· Source

• Not yet recruiting

  Evaluation of Efficacy and Safety De-escalation Versus Standard Adjuvant Chemotherapy in Patients With Low Risk Localized Gastroesophageal Adenocarcinoma

  NCT06933966· Phase 2· Centre Leon Berard· Source

• Completed

  Infectious Complications After Esophagectomy

  NCT06911658· Assistance Publique - Hôpitaux de Paris· Source

• Completed

  C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People With Relapsed or Refractory Diffuse Large B Cell Lymphoma

  NCT05896163· Phase 1/2· Pfizer Inc.· Source

• Completed

  An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma

  2024-511949-19-00· Phase 1· Sairopa B.V.· Source

• Completed

  IFM 2020-01 (Isamyp) Efficacity assessment of isatuximab plus pomalidomide and dexamethasone in patients with AL amyloidosis who didn't reach at least a very good partial response with their previous treatment

  NCT05066607· Phase 2· Intergroupe Francophone Du Myelome· Source

• Completed

  Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.

  NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up

  NCT06592846· The Lymphoma Academic Research Organisation· Source

• Active, not recruiting

  RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  NCT06243458· Phase 2· GCP-Service International West GmbH· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC injection in Adult Participants with Moderate to Severe Atopic Dermatitis

  NCT05999799· Phase 2· Glaxosmithkline Research & Development Limited· Source

• Completed

  A first-in-human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy in subjects with relapsed/refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

  NCT05961839· Phase 1· Schrodinger Inc.· Source

• Completed

  A trial to find out if vidutolimod together with cemiplimab is safe and if it works in adult participants with advanced cancer or metastatic cancer

  NCT04916002· Phase 2· Regeneron Pharmaceuticals Inc.· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Recruiting

  A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

  NCT06285318· Janssen-Cilag Ltd.· Source

• Completed

  AN OPEN-LABEL, MULTICENTER, PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED, REFRACTORY, OR NEWLY DIAGNOSED CANCERS

  NCT04553692· Phase 1· IGM Biosciences Inc.· Source

• Terminated

  Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

  NCT05625087· Phase 2· UNICANCER· Source

• Completed

  Detection of tumor DNA in the blood of patients receiving standard therapy for hormone receptorpositive (HR+) non-HER2 expressing (HER2-) metastatic breast cancer as a tool to select those who may benefit from the next course of fulvestrant in combination with alpelisib or ribociclib.

  2022-502372-22-01· Phase 2· Unicancer· Source

• Completed

  A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

  NCT05487248· Jules Bordet Institute· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· LEO Pharma· Source

• Completed

  A study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus lomustine in patients with glioblastoma at first progression

  NCT03779230· Phase 1/2· Philogen S.p.A.· Source

• Completed

  Ophthalmological Adverse Events of Tralokinumab in AD

  NCT05682976· Nantes University Hospital· Source

• Completed

  Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

  NCT05583552· Phase 2· GCP-Service International West GmbH· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

  NCT05383170· Phase 1/2· Cytovation AS· Source

• Completed

  Dupilumab step-down strategy to maintain remission in adult and adolescents patients with atopic dermatitis: a non-inferiority randomized trial

  2022-501179-23-00· Phase 4· Centre Hospitalier Universitaire De Nantes· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Nantes University Hospital· Source

• Completed

  Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

  NCT05577182· Phase 1· Incyte Corporation· Source

• Completed

  SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease

  NCT05628233· Phase 2· Sensorion· Source

• Completed

  A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

  NCT05656911· Phase 2· Bayer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT05620823· Phase 3· Incyte Corporation· Source

• Completed

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  2022-500652-37-00· Phase 2· Agenus Inc.· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Terminated

  A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

  NCT05568225· Phase 2· Forma Therapeutics, Inc.· Source

• Active, not recruiting

  A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

  NCT05490446· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Withdrawn

  A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

  NCT05572463· Phase 1/2· Innovent Biologics (Suzhou) Co. Ltd.· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

  NCT05061134· Phase 2· AstraZeneca· Source

• Completed

  Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

  NCT05393037· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

  2023-508357-58-00· Phase 1/2· Sanofi-Aventis Recherche & Developpement· Source

• Completed

  A Phase 2 study of durcabtagene autoleucel, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma

  NCT05172596· Phase 2· Novartis Pharma AG· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1)

  NCT04905407· Phase 2· Syros Pharmaceuticals Inc.· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

  NCT05116202· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

  NCT04988841· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Terminated

  SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study

  NCT05010850· SafeHeal Inc· Source

• Terminated

  An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

  NCT04586244· Phase 2· Incyte Corporation· Source

• Completed

  A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

  NCT04984356· Phase 1· Allotera Therapeutics· Source

• Completed

  European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

  NCT05041803· Phase 3· Sun Pharmaceutical Industries, Inc.· Source

• Completed

  Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

  NCT05070208· Acute Leukemia French Association· Source

Showing 50 of 144.

Conditions

Diseases this institution publishes on or runs trials for.

• Acute myeloid leukaemia48 works · 51 trials
• Melanoma39 works · 32 trials
• Myelodysplastic syndromes38 works · 35 trials
• Acute lymphoblastic leukaemia29 works · 17 trials
• Myeloproliferative neoplasms28 works · 35 trials
• Crohn's disease27 works · 6 trials
• Multiple myeloma25 works · 25 trials
• Psoriasis22 works · 1 trial
• Hodgkin lymphoma15 works · 6 trials
• Cytomegalovirus infection13 works · 0 trials
• Follicular lymphoma12 works · 17 trials
• Chronic myeloid leukaemia10 works · 12 trials
• Aplastic anaemia10 works · 4 trials
• Dermatomyositis and polymyositis (myositis)5 works · 2 trials
• Mantle cell lymphoma4 works · 13 trials